Effects of chronic topical application of 12-O-tetradecanoylphorbol-13-acetate on the skin and internal organs of SENCAR mice.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: National Institute of Environmental Health Sciences Country of Publication: United States NLM ID: 0330411 Publication Model: Print Cited Medium: Print ISSN: 0091-6765 (Print) Linking ISSN: 00916765 NLM ISO Abbreviation: Environ Health Perspect Subsets: MEDLINE
    • Publication Information:
      Original Publication: Research Triangle Park, N. C. National Institute of Environmental Health Sciences.
    • Subject Terms:
      Mice, Inbred Strains*; Skin/*drug effects ; Tetradecanoylphorbol Acetate/*toxicity; Administration, Topical ; Amyloidosis/chemically induced ; Animals ; Female ; Hyperplasia ; Immune System/drug effects ; Male ; Mice ; Nephritis, Interstitial/chemically induced ; Skin/pathology ; Tetradecanoylphorbol Acetate/administration & dosage
    • Abstract:
      Repetitive topical applications of 2 micrograms 12-O-tetradecanoylphorbol-13-acetate (TPA) twice weekly for 37 to 52 weeks induced a sustained epidermal hyperplasia, hyperplasia of hair follicles, and increased dermal cellularity in SENCAR mice. In addition, after 52 weeks of protracted promoter treatment most animals developed generalized amyloidosis involving liver and spleen, as well as interstitial nephritis. Severe pyelonephritis and papillary necrosis were also frequently seen. Reactive lymphoid hyperplasia was also a frequent finding. Chronic administration of TPA is not an innocuous treatment affecting only the interfollicular epidermis. The general effect of the promoter on the animals was a marked decrease in their longevity, probably through impairment of the immune system.
    • References:
      Carcinogenesis. 1981;2(10):999-1006. (PMID: 7296766)
      J Invest Dermatol. 1981 Aug;77(2):230-4. (PMID: 6792294)
      Carcinogenesis. 1981;2(12):1353-8. (PMID: 7326834)
      Carcinog Compr Surv. 1982;7:637-42. (PMID: 6978182)
      Lab Invest. 1983 Jan;48(1):1-4. (PMID: 6401828)
      Lab Invest. 1983 Feb;48(2):231-40. (PMID: 6337302)
      Am J Surg Pathol. 1983 Sep;7(6):543-53. (PMID: 6353952)
      Cancer Res. 1985 Jun;45(6):2753-9. (PMID: 3986807)
      Cancer Res. 1973 Feb;33(2):269-86. (PMID: 4347466)
      Cancer Res. 1977 Nov;37(11):4195-201. (PMID: 409492)
      Virchows Arch B Cell Pathol Incl Mol Pathol. 1979 May 4;30(1):33-42. (PMID: 37642)
      Cancer. 1980 Jan 1;45(1):137-48. (PMID: 7350998)
      Arch Dermatol. 1980 Jan;116(1):41-5. (PMID: 6444351)
      Am J Pathol. 1980 Mar;98(3):639-48. (PMID: 7361848)
      Br J Dermatol. 1981 Feb;104(2):131-9. (PMID: 6971116)
      Am J Surg Pathol. 1981 Jun;5(4):343-52. (PMID: 7270782)
      Carcinogenesis. 1980 May;1(5):399-406. (PMID: 6168406)
      Cancer Res. 1981 Nov;41(11 Pt 1):4437-40. (PMID: 6796260)
    • Accession Number:
      NI40JAQ945 (Tetradecanoylphorbol Acetate)
    • Publication Date:
      Date Created: 19860901 Date Completed: 19870115 Latest Revision: 20181113
    • Publication Date:
      20240829
    • Accession Number:
      PMC1474246
    • Accession Number:
      10.1289/ehp.866875
    • Accession Number:
      3780635